Tag Archives: Pharmaceutical law

AMC v. Myriad – “Laws of Nature” Exception Does Not Include Isolated DNA

Posted on July 31, 2011 by Warren Woessner

As noted in my last “flash” post, a divided three-judge Fed. Cir. panel (Judges Lourie, Bryson and Moore) issued an opinion holding that the isolated DNA sequences and the drug-screening method claimed by Myriad are patentable subject matter, not natural … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , , , | 2 Comments

Caraco – The Little Counterclaim That Could?

Posted on June 16, 2011 by Warren Woessner

I normally try to steer clear of issues raised in Hatch-Waxman litigation between the “innovators” and the “generics,” unless it raises specific points of patent law of general interest – there is just so much of it, and other blogs … Continue reading →

Posted in Hatch-Waxman | Tagged , , , , , , , , , , , , , , | 2 Comments

Happy Birthday Patents4Life – We Are 2!

Posted on March 3, 2011 by Warren Woessner

Now some of them are not yet carved in judicial stone, being at various stages of appeal, but the sum of KSR,  Bilski (well, I guess it was more pro-patent than the strict M or T test it replaced with … Continue reading →

Posted in About SLW | Tagged , , , , , , , , , , , , , , , , , , , , | 1 Comment

Pharmaceutical Patent Protection and Enforcement Conference

Posted on September 21, 2010 by Warren Woessner

Warren Woessner will be a speaker on September 28th at Q1 Productions’ “Pharmaceutical Patent Protection and Enforcement Conference” in Baltimore, MD.  Warren will speak on “Myriad: The District Court’s Opinion & Road Ahead”, a topic that has been the subject … Continue reading →

Posted in Conferences and Classes | Tagged , , , | Leave a comment